News | February 02, 2012

New Data for Symphony Presented at Society of Thoracic Surgeons 2012



February 2, 2012 — Abiomed Inc. announced that initial clinical data from the safety study for Symphony was presented by Renzo Cecere, M.D., FRCSC, FACS, associate professor of surgery at McGill University, during the late-breaking clinical trials session at the Society of Thoracic Surgeons (STS) 2012 meeting in Fort Lauderdale, Fla.

The presentation, Initial Safety Trial of an Implantable, Synchronous, Partial Circulatory Support Device: Symphony,” discussed the initial clinical data from the Symphony safety trial being conducted outside of the United States, and was presented during one of the four late-breaking clinical trials sessions at the STS meeting.

The presentation included analysis of the initial first-in-man experience, originally announced in December 2011, which demonstrated feasibility of the synchronized, implantable heart pump Symphony. The analysis indicated a marked improvement in cardiac output, improved renal function, short intensive care unit (ICU) stay and early patient mobility post implant.

“The concept of a minimally invasive implantable pump for patients in chronic heart failure, coupled with the ability to remodel the heart, is unique and groundbreaking and we are very pleased with the initial findings of Symphony,” said Cecere.

Symphony is designed to treat approximately 90,000 of the 1.6 million New York Heart Association (NYHA) Class III chronic heart failure patients by improving patient hemodynamics and potentially quality of life. The device is designed with the primary goal of lowering hospital costs by stabilizing the progression of heart failure and/or recovering/remodeling the heart.

Symphony is not currently approved for use in the United States.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init